Stirling fishes for trout
Tuesday, 15 July, 2008
Stirling Products North America, a subsidiary of Perth's Stirling Products [ASX: STI] has demonstrated the results of its research into treatment of Loma microsporidial gill disease at an American Fisheries Society meeting.
Loma gill disease, caused by Loma salmonae, is an untreatable disease commonly found in farmed fish, particularly in Pacific salmon and trout.
Research conducted by Stirling demonstrates that the company's ProVale product was more effective at inhibiting Loma infection in rainbow trout when compared with unlicensed products.
ProVale is a beta glucan extract designed to stimulate the immune system.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
